arrow
G

Gerald Gartlehner

Humanitas University
H指数:71
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Maternal vaccination against COVID-19, influenza, pertussis, and respiratory syncytial virus: a scoping review

针对COVID-19、流感、百日咳和呼吸道合胞病毒的母亲疫苗接种:一项范围综述

2026-09-290
OAAI
Artificial Intelligence-enabled GRADE: how the GRADE Working Group will use automation to rate the certainty of evidence of intervention effects

人工智能赋能的GRADE:GRADE工作组将如何利用自动化对干预效应的证据确定性进行评级

2026-08-010
PRE
Cochrane Evaluation of (Semi-) Automated Review Methods (CESAR): Protocol for an adaptive platform study within reviews

Cochrane评价(半)自动化综述方法(CESAR):在综述中进行的适应性平台研究的方案

2026-06-190
OA
Position Statement on Artificial Intelligence (AI) Use in Evidence Synthesis Across Cochrane, the Campbell Collaboration, JBI, and the Collaboration for Environmental Evidence 2025

关于人工智能(AI)在证据综合中应用的立场声明(2025)(涵盖考克兰协作网、坎贝尔协作网、JBI及环境证据协作网)

2025-11-100
OAAI
Position statement on artificial intelligence (AI) use in evidence synthesis across Cochrane, the Campbell Collaboration, JBI, and the Collaboration for Environmental Evidence 2025

关于人工智能 (AI) 在Cochrane,Campbell合作,JBI和环境证据2025合作中的证据合成中的立场声明

2025-11-011
PRE
Position statement on artificial intelligence (AI) use in evidence synthesis across Cochrane, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence 2025

关于人工智能(AI)在证据综合中应用的立场声明(2025年),涉及Cochrane、Campbell Collaboration、JBI和Collaboration for Environmental Evidence。

2025-11-010
OAAI
Evidence-based Decision Analysis Guiding Clinical Guidelines for an Organized Population-based Screening for Colorectal Cancer

基于证据的决策分析指导针对有组织的基于人群的结直肠癌筛查的临床指南

2025-08-080
PRE
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
2025-02-120
PRE
An exploration of available methods and tools to improve the efficiency of systematic review production: a scoping review

探索提高系统评价生产效率的可用方法和工具: 范围界定审查

2024-09-181
OA